Related Experiment Video
Updated: Mar 21, 2026

14:40
Optogenetic Manipulation of Neuronal Activity to Modulate Behavior in Freely Moving Mice
Published on: October 27, 2020
20.4K
Optogenetic modulation in stroke recovery
Arjun V Pendharkar1, Sabrina L Levy1, Allen L Ho1
1Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.
Neurosurgical Focus
|May 3, 2016
Summary
Optogenetics offers precise neuromodulation for stroke recovery. This review explores its potential, preclinical evidence, and challenges for clinical translation in stroke rehabilitation.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Regenerative Medicine
Background:
- Stroke significantly impacts morbidity, mortality, and healthcare costs in the US.
- Many preclinical stroke recovery strategies fail in clinical trials.
- Optogenetics provides precise circuit-level neuromodulation for potential therapeutic applications.
Purpose of the Study:
- To review the conceptual background of optogenetics for stroke recovery.
- To examine the preclinical evidence supporting optogenetics in stroke.
- To discuss translational challenges and considerations for clinical application.
Main Methods:
- Review of existing literature on optogenetics and stroke.
- Analysis of preclinical studies demonstrating optogenetic neuromodulation.
- Discussion of translational science principles.
Main Results:
- Optogenetics enables targeted control of neural circuits relevant to motor function.
- Preclinical studies show promise for optogenetics in enhancing stroke recovery.
- Significant hurdles remain for successful clinical translation.
Conclusions:
- Optogenetics is a powerful tool with potential for stroke recovery.
- Further research is needed to overcome translational barriers.
- Clinical application of optogenetics could revolutionize stroke rehabilitation.
Keywords:
ArchT = archaerhodopsinBDNF = brain-derived neurotrophic factorCAP-23 = cytoskeleton-associated protein 23CNO = clozapine-N-oxideDREADDDREADD = designer receptor exclusively activated by designer drugsEGF = epidermal growth factorFGF-2 = basic fibroblast growth factor 2GABA = γ-aminobutyric acidGAP-43 = growth-associated protein 43GDF10 = growth differentiation factor 10GDNF = glial cell line–derived neurotrophic factorIGF1 = insulin-like growth factor 1MARCKS = myristoylated alanine-rich protein kinase C substrateNGF = nerve growth factorNTF3 = neurotrophin-3WGA = wheat germ agglutinindesigner receptor exclusively activated by designer drugsiM1 = ipsilesional primary motor cortexischemianeuroregenerationoptogeneticsplasticitystroke
